Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

Moderna (MRNA) stock jumped more than 6% on Wednesday after the US Food and Drug Administration agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced ...

This ends a drawn out legal battle brought by Genevant and Arbutus against Moderna under a week before the jury trial was set to begin.

Add Yahoo as a preferred source to see more of our stories on Google. The Moderna logo appears on a laptop computer screen in this photo illustration in Athens, Greece, on February 9, 2026. Photo ...

Moderna Inc agreed to pay US$950 million to settle litigation related to the delivery technology behind its Covid-19 shot, removing a looming financial risk for the struggling vaccine maker.

The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the ...